Close

I-Mab Biopharma (IMAB) Reports Prelim Phase 2 Clinical Data of Uliledlimab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. GM
2. TSLA
3. NVDA
4. SPY
5. CDNS
6. ADBE
7. CPRI
8. AAPL
9. TPR
10. LMT


Go back to I-Mab Biopharma (IMAB) Reports Prelim Phase 2 Clinical Data of Uliledlimab
(NASDAQ: IMAB) Delayed: 1.80 --0 (-0%)
Previous Close $1.80    52 Week High $ 
Open $1.80    52 Week Low $ 
Day High $1.80    P/E N/A 
Day Low $1.80    EPS $ 
Volume 3